The idea of incorporating music into psychedelic therapy isn’t new; it was a point of great interest to music therapists in the 60s. But Kaelen is trying to ground it in a solid scientific framework. He explained that the need to include music in these trials is borne directly from the rising interest in studying […]
Speakers at an event in north London describe their positive experiences of drugs such as psilocybin and LSD, part of a wider resurgence
It may take some time to get the general public used to the idea of treating mental illness with drugs many associate with hard partying, but the medical community is jumping aboard the psychedelics train
First modern scans of people high on psychedelic drug has given researchers unprecedented insight into neural basis for its effects
Psilocybin frees the brain from its rigid patterns and ego-driven assumptions, and allows the user to look at the world — and him or herself — from a whole new perspective. Many mushroom experiences also are accompanied by waves of good feelings and psychedelic visions of sound and color. These results build on other […]
“These are remarkable compounds, with I think remarkable implications, if we can understand how they work and why they work,” says Roland Griffiths, a scientist at Johns Hopkins University, where some of the world’s leading psychedelic research is taking place. Psilocybin mushrooms provoke mystical experiences and spiritual journeys when the body breaks the chemical […]
Psilocybin may be useful in treating anxiety, addiction, and depression, and in studying the neurobiology of mystical experience.
On an April Monday in 2010, Patrick Mettes, a fifty-four-year-old television news director being treated for a cancer of the bile ducts, read an article on the front page of the Times that would change his death. His diagnosis had come three years earlier, shortly after his wife, Lisa, noticed that the whites of his eyes had turned yellow. By 2010, the cancer had spread to Patrick’s lungs and he was buckling under the weight of a debilitating chemotherapy regimen and the growing fear that he might not survive. The article, headlined “Hallucinogens Have Doctors Tuning in Again,” mentioned clinical trials at several universities, including N.Y.U., in which psilocybin—the active ingredient in so-called magic mushrooms—was being administered to cancer patients in an effort to relieve their anxiety and “existential distress.” One of the researchers was quoted as saying that, under the influence of the hallucinogen, “individuals transcend their primary identification with their bodies and experience ego-free states . . . and return with a new perspective and profound acceptance.” Patrick had never taken a psychedelic drug, but he immediately wanted to volunteer. Lisa was against the idea. “I didn’t want there to be an easy way out,” she recently told me. “I wanted him to fight.”
The revival of psychedelic research today owes much to the respectability of its new advocates. At sixty-eight, Roland Griffiths, who was trained as a behaviorist and holds senior appointments in psychiatry and neuroscience at Hopkins, is one of the nation’s leading drug-addiction researchers. More than six feet tall, he is rail-thin and stands bolt upright; the only undisciplined thing about him is a thatch of white hair so dense that it appears to have held his comb to a draw. His long, productive relationship with nida has resulted in some three hundred and fifty papers, with titles such as “Reduction of Heroin Self-Administration in Baboons by Manipulation of Behavioral and Pharmacological Conditions.” Tom Insel, the director of the N.I.M.H., described Griffiths as “a very careful, thoughtful scientist” with “a reputation for meticulous data analysis. So it’s fascinating that he’s now involved in an area that other people might view as pushing the edge.”
The lab at Hopkins is currently conducting a study of particular interest to Griffiths: examining the effect of psilocybin on long-term meditators. The study plans to use fMRI—functional magnetic-resonance imaging—to study the brains of forty meditators before, during, and after they have taken psilocybin, to measure changes in brain activity and connectivity and to see what these “trained contemplatives can tell us about the experience.” Griffiths’s lab is also launching a study in collaboration with N.Y.U. that will give the drug to religious professionals in a number of faiths to see how the experience might contribute to their work. “I feel like a kid in a candy shop,” Griffiths told me. “There are so many directions to take this research. It’s a Rip Van Winkle effect—after three decades of no research, we’re rubbing the sleep from our eyes.”
“Ineffability” is a hallmark of the mystical experience. Many struggle to describe the bizarre events going on in their minds during a guided psychedelic journey without sounding like either a New Age guru or a lunatic. The available vocabulary isn’t always up to the task of recounting an experience that seemingly can take someone out of body, across vast stretches of time and space, and include face-to-face encounters with divinities and demons and previews of their own death.
Volunteers in the N.Y.U. psilocybin trial were required to write a narrative of their experience soon after the treatment, and Patrick Mettes, having worked in journalism, took the assignment seriously. His wife, Lisa, said that, after his Friday session, he worked all weekend to make sense of the experience and write it down.
When Mettes arrived at the treatment room, at First Avenue and Twenty-fifth Street, Tony Bossis and Krystallia Kalliontzi, his guides, greeted him, reviewed the day’s plan, and, at 9 A.M., presented him with a small chalice containing the pill. None of them knew whether it contained psilocybin or the placebo. Asked to state his intention, Mettes said that he wanted to learn to cope better with the anxiety and the fear that he felt about his cancer. As the researchers had suggested, he’d brought a few photographs along—of Lisa and him on their wedding day, and of their dog, Arlo—and placed them around the room.
David Nutt, former government chief drugs adviser, says banning of legal highs has already been destructive to Parkinson’s and anti-smoking research
A music festival might not seem an obvious place to see and hear science, but Latitude was full of it.
For 40 years, Amanda Feilding, Countess of Wemyss and March, has believed psychedelics are an effective treatment for depression and anxiety. Now a growing number of scientists agree